Skip to main content
Premium Trial:

Request an Annual Quote

Nicholas Naclerio Lands at Parallele as President; Keith Weikel elected to LabCorp Board; and Others

NEW YORK, July 23 - Nicholas Naclerio has been appointed president of Parallele BioScience, the company said Tuesday.


Naclerio comes to the South San Francisco genotyping company from a stint as an independent consultant for life sciences and venture capital companies. Before that, he was chief business officer of protein chip company Zyomyx for a short time between November 2001 and early 2002.  Naclerio was an executive at Motorola, where he founded the company's life sciences business unit and led the launch of its CodeLink microarray platform, between  the late 1990s and 2001. He was an assistant director at the US Government's Defense Advanced Research Projects agency before joining Motorola. Naclerio has also served on the boards of Orchid BioScience, Genometrix, the SNP Consortium, and Clinical Microsensors, which Motorola acquired in 2000.


Tom Willis, Paralelle's current president, has been appointed chief scientific officer. Mostofa Ronaghi, a co-founder of the company, will leave the board of directors, and will join the company's scientific advisory board.


Keith Weikel has been elected to the board of directors of Laboratory Corporation of America, a major diagnostic testing lab that uses genomics, the company said July 18.


Weikel is senior executive vice president and chief operating officer of Manor Care, of Toledo, Ohio. Prior to this, Weikel has held senior-level positions at the Health Care and Retirement Corporation of America, American Medical International, and the US Department of Health and Human Services, where he served as the Commissioner of Medical Services Administration.


Gioachhino De Chirico has been appointed president and chief operating officer of Immucor, a provider of instrument-reagent systems to the blood transfusion industry; and Didier Lanson has been appointed director of European Operations, a post formerly held by De Chirico, the company said July 18.


Before joining Immucor, De Chirico was a general manager at Ortho Clinical Diagnostics.


Lanson was CEO of GenOdysee, a functional genomics company, between November 1999 and April 2002. Prior to this, he was vice president of global operations and International Affairs for Systemix, a subsidiary of Novartis. He was CEO of Diagnostics Transfusion, a company that sold blood bank reagents, between 1981 and 1987.


Kevin Shutes has been named president of the Celex Wire & Tube Cutting division of Point Technologies, the Boulder, Colo., company said July 17.


Celex, of Gibbon, Minnesota, makes Point Technologies tungsten accelerator-brand microarray spotting pins, which are about a quarter the width of a human hair.


Shutes was previously general manager of the Celex division.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.